ATE496062T1 - Verbindungen zur proteasomenzymhemmung - Google Patents

Verbindungen zur proteasomenzymhemmung

Info

Publication number: ATE496062T1
Authority: AT; Austria
Prior art keywords: compounds; peptide; proteasome; inhibition; based compounds
Prior art date: 2004-08-06

Application number

AT05784484T

Other languages

English (en)

Inventor

Mark Smyth

Guy Laidig

Original Assignee

Onyx Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-06

Filing date

2005-08-08

Publication date

2011-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35502451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE496062(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-08-08 Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc

2011-02-15 Application granted granted Critical

2011-02-15 Publication of ATE496062T1 publication Critical patent/ATE496062T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 6
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title abstract 2
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title abstract 2
241000006479 Cyme Species 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
230000000694 effects Effects 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 abstract 1
108090000604 Hydrolases Proteins 0.000 abstract 1
102000004157 Hydrolases Human genes 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000037012 chymotrypsin-like activity Effects 0.000 abstract 1
150000002118 epoxides Chemical class 0.000 abstract 1
238000007306 functionalization reaction Methods 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
230000035407 negative regulation of cell proliferation Effects 0.000 abstract 1
239000012038 nucleophile Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)

AT05784484T 2004-08-06 2005-08-08 Verbindungen zur proteasomenzymhemmung ATE496062T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US59940104P	2004-08-06	2004-08-06
US61000104P	2004-09-14	2004-09-14
US11/106,879 US7232818B2 (en)	2004-04-15	2005-04-14	Compounds for enzyme inhibition
PCT/US2005/028246 WO2006017842A1 (en)	2004-08-06	2005-08-08	Compounds for proteasome enzyme inhibition

Publications (1)

Publication Number	Publication Date
ATE496062T1 true ATE496062T1 (de)	2011-02-15

Family

ID=35502451

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05784484T ATE496062T1 (de)	2004-08-06	2005-08-08	Verbindungen zur proteasomenzymhemmung

Country Status (24)

Country	Link
US (12)	US7232818B2 (de)
EP (4)	EP3101026B1 (de)
JP (2)	JP4743720B2 (de)
KR (3)	KR101354280B1 (de)
CN (1)	CN102286070B (de)
AT (1)	ATE496062T1 (de)
AU (1)	AU2005271232B2 (de)
BR (2)	BR122020008634B8 (de)
CA (1)	CA2589765C (de)
CY (3)	CY1116771T1 (de)
DE (1)	DE602005026019D1 (de)
DK (2)	DK1781688T3 (de)
ES (2)	ES2525248T3 (de)
FR (1)	FR16C0017I2 (de)
HU (2)	HUE038005T2 (de)
IL (3)	IL181127A (de)
LT (2)	LT3101026T (de)
LU (1)	LU93015I2 (de)
NO (2)	NO341015B1 (de)
PL (2)	PL1781688T3 (de)
PT (2)	PT3101026T (de)
SG (2)	SG10201701794UA (de)
SI (2)	SI3101026T1 (de)
WO (1)	WO2006017842A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7176232B2 (en)	2002-06-24	2007-02-13	The Regents Of The University Of California	Salinosporamides and methods for use thereof
US7232818B2 (en) *	2004-04-15	2007-06-19	Proteolix, Inc.	Compounds for enzyme inhibition
US8198270B2 (en) *	2004-04-15	2012-06-12	Onyx Therapeutics, Inc.	Compounds for proteasome enzyme inhibition
CN103554222A (zh)	2004-04-15	2014-02-05	欧尼斯治疗公司	用于抑制蛋白酶体酶的化合物
AU2005243140A1 (en) *	2004-05-10	2005-11-24	Proteolix, Inc.	Synthesis of amino acid keto-epoxides
ES2510840T3 (es) *	2004-05-10	2014-10-21	Onyx Therapeutics, Inc.	Compuestos para la inhibición enzimática del proteosoma
EP1830838B1 (de)	2004-12-03	2012-10-03	Dana-Farber Cancer Institute, Inc.	Zubereitungen und verfahren zur behandlung von neoplastischen erkrankungen
DE602005026556D1 (de) *	2004-12-07	2011-04-07	Proteolix Inc	Zusammensetzung zur proteasomhemmung
JP5436860B2 (ja) *	2005-11-09	2014-03-05	オニキスセラピューティクス，インク．	酵素阻害のための化合物
MY183014A (en) *	2006-06-19	2021-02-05	Onyx Therapeutics Inc	Compounds for enzyme inhibition
WO2008006819A2 (en) *	2006-07-14	2008-01-17	Vib Vzw	Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
US7642369B2 (en) *	2006-09-12	2010-01-05	University Of Kentucky Research Foundation	Epoxyketone-based immunoproteasome inhibitors
KR20150131405A (ko) *	2007-10-04	2015-11-24	오닉스 세라퓨틱스, 인크.	결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
AU2013203566B2 (en) *	2007-10-04	2016-10-13	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2016231532B2 (en) *	2007-10-04	2018-05-10	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US8394816B2 (en) *	2007-12-07	2013-03-12	Irene Ghobrial	Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2088205A1 (de)	2008-02-11	2009-08-12	Institut National De La Sante Et De La Recherche Medicale (Inserm)	PSMB10: Diagnosemarker und therapeutisches Target für chronische Abstoßung
US7635773B2 (en)	2008-04-28	2009-12-22	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions
US7910616B2 (en)	2008-05-12	2011-03-22	Nereus Pharmaceuticals, Inc.	Proteasome inhibitors
JP5675629B2 (ja)	2008-10-21	2015-02-25	オニキスセラピューティクス，インク．ＯｎｙｘＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ペプチドエポキシケトンを用いた併用療法
AR075899A1 (es)	2009-03-20	2011-05-04	Onyx Therapeutics Inc	Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US20110009332A1 (en) *	2009-07-09	2011-01-13	Southwest Research Institute	Therapeutic Treatment Of Wounds
GB0914883D0 (en)	2009-08-26	2009-09-30	Univ Belfast	Compound
WO2011060179A1 (en)	2009-11-13	2011-05-19	Onyx Therapeutics, Inc	Use of peptide epoxyketones for metastasis suppression
CA2791651C (en)	2010-03-01	2019-08-20	Onyx Therapeutics, Inc.	Compounds for immunoproteasome inhibition
AU2011245630B2 (en)	2010-04-07	2014-07-03	Onyx Therapeutics, Inc.	Crystalline peptide epoxyketone immunoproteasome inhibitor
US9126997B1 (en)	2010-09-07	2015-09-08	Northwestern University	Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
WO2012135528A2 (en)	2011-03-29	2012-10-04	Texas Tech University System	Galectin-3c combination therapy for human cancer
WO2013009923A1 (en) *	2011-07-13	2013-01-17	Creighton University	Methods of promoting neuron growth
CA2855368A1 (en)	2011-11-11	2013-05-16	Millennium Pharmaceuticals, Inc.	Biomarkers of response to proteasome inhibitors
WO2013071142A1 (en)	2011-11-11	2013-05-16	Millennium Pharmaceuticals, Inc.	Biomarkers of response to proteasome inhibitors
JP6215235B2 (ja)	2012-01-24	2017-10-18	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	癌の治療方法
EP4083075A1 (de)	2012-02-15	2022-11-02	CyDex Pharmaceuticals, Inc.	Verfahren zur herstellung von cyclodextrinderivaten
FI2662094T3 (fi)	2012-05-08	2024-06-26	Onyx Therapeutics Inc	Syklodekstriinin kompleksointimenetelmiä peptidiproteasomiestäjien formulointiin
US9309283B2 (en)	2012-07-09	2016-04-12	Onyx Therapeutics, Inc.	Prodrugs of peptide epoxy ketone protease inhibitors
EP2874606B1 (de)	2012-07-18	2019-03-06	Onyx Therapeutics, Inc.	Liposomale zusammensetzungen von proteasomhemmern auf epoxyketonbasis
US20150218212A1 (en) *	2012-08-21	2015-08-06	Fluorinov Pharma Inc.	Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
MX360192B (es)	2012-10-22	2018-10-24	Cydex Pharmaceuticals Inc	Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas.
AU2014244333B2 (en)	2013-03-13	2019-02-07	Sanofi-Aventis U.S. Llc	Compositions comprising anti-CD38 antibodies and carfilzomib
AR095426A1 (es)	2013-03-14	2015-10-14	Onyx Therapeutics Inc	Inhibidores tripeptídicos de la epoxicetona proteasa
SG11201507106PA (en)	2013-03-14	2015-10-29	Onyx Therapeutics Inc	Dipeptide and tripeptide epoxy ketone protease inhibitors
JP6851826B2 (ja)	2013-07-19	2021-03-31	オニキスセラピューティクス，インク．ＯｎｙｘＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	がんの治療のためのｐｉｍキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤
CN103360348B (zh) *	2013-07-25	2015-06-24	苏州鹏旭医药科技有限公司	一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
EP3041832A1 (de) *	2013-09-06	2016-07-13	Sandoz AG	Stereoselektive synthese von diolen und triolen durch eine mannich-reaktion und deren verwendung bei der synthese von carfilzomib
US20160215016A1 (en) *	2013-09-06	2016-07-28	Sandoz Ag	Synthesis of peptide epoxy ketones
WO2015121769A1 (en)	2014-02-13	2015-08-20	Ranbaxy Laboratories Limited	Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
CN103864889B (zh) *	2014-04-04	2017-01-11	重庆泰濠制药有限公司	环氧酮化合物、其制备方法及卡非佐米的制备方法
JP6914188B2 (ja)	2014-08-22	2021-08-04	サイデックス・ファーマシューティカルズ・インコーポレイテッド	分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
US10329325B2 (en)	2014-09-24	2019-06-25	Biophore India Pharmaceuticals Pvt. Ltd	Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
WO2016069479A1 (en)	2014-10-27	2016-05-06	Apicore Us Llc	Methods of making carfilzomib and intermediates thereof
CN104402973A (zh) *	2014-11-24	2015-03-11	重庆泰濠制药有限公司	一种卡非佐米无定型晶的制备方法
ES2742196T3 (es)	2014-12-02	2020-02-13	Fresenius Kabi Oncology Ltd	Un procedimiento para la purificación de carfilzomib
US10301353B2 (en)	2014-12-31	2019-05-28	Dr. Reddy's Laboratories Limited	Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
US10544189B2 (en)	2015-04-22	2020-01-28	Msn Laboratories Private Limited	Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide
EP3297678B1 (de)	2015-05-21	2021-07-07	Laurus Labs Limited	Verbesserte verfahren zur herstellung von carfilzomib oder pharmazeutisch akzeptablen salzen daraus
CN106317188A (zh) *	2015-06-18	2017-01-11	重庆医药工业研究院有限责任公司	一种制备卡非佐米无定型物的方法
WO2017032487A1 (en)	2015-08-27	2017-03-02	Technische Universität München	Proteasome inhibitor comprising a signal-emitting moiety
US20180362580A1 (en)	2015-12-11	2018-12-20	Mylan Laboratories Limited	Crystalline and amorphous forms of carfilzomib
TWI636052B (zh) *	2015-12-31	2018-09-21	中化合成生技股份有限公司	無定形卡非佐米(i)的製備方法
WO2017147410A1 (en)	2016-02-25	2017-08-31	Amgen Inc.	Compounds that inhibit mcl-1 protein
TWI759301B (zh) *	2016-05-24	2022-04-01	美商安美基公司	聚乙二醇化卡非佐米化合物
EP3494126A1 (de)	2016-08-02	2019-06-12	Synthon BV	Verfahren zur herstellung von carfilzomib
ES2842575T3 (es)	2016-08-05	2021-07-14	Amgen Inc	Síntesis de (S)-2-amino-4-metil-1-((R)-2-metiloxiran-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma
CN109689635A (zh)	2016-09-14	2019-04-26	费森尤斯卡比肿瘤学有限公司	一种用于纯化卡非佐米中间体的方法
ES2978159T3 (es)	2016-09-16	2024-09-06	Hsf Pharmaceuticals	Inhibidores de factores de choque térmico (HSF) y usos de los mismos
EP3330260A1 (de)	2016-12-01	2018-06-06	Enantia, S.L.	Verfahren zur herstellung eines zwischenprodukts zur synthese von i. a. carfilzomib
JP2020533382A (ja)	2017-09-14	2020-11-19	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	癌の組合せ治療
US11241502B2 (en)	2017-11-16	2022-02-08	Amgen Inc.	Stable compositions of pegylated carfilzomib compounds
JP7422673B2 (ja) *	2017-12-08	2024-01-26	ニューロジーエックスエルエルシー	アルツハイマー病についての同調させた細胞周期遺伝子発現試験および関連治療法
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
US10689416B2 (en)	2017-12-30	2020-06-23	Unity Biotechnology, Inc.	Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
EP3548504B1 (de) *	2017-12-30	2021-07-21	Unity Biotechnology, Inc.	Peptidbasierte proteasominhibitoren zur behandlung von durch seneszente zellen vermittelte erkrankungen und zur behandlung von krebs
CA3103920C (en) *	2018-06-22	2025-09-16	Ucl Business Ltd	COMPOUNDS FOR TREATING DISEASES MEDIATED BY ALPHA-1 ANTITRYPSIN
WO2021072212A1 (en) *	2019-10-11	2021-04-15	Mayo Foundation For Medical Education And Research	Proteasome inhibitors
CA3175499A1 (en) *	2020-04-21	2021-10-28	University Of Rochester	Inhibitors of human epididymus protein 4
US20250302954A1 (en)	2022-05-11	2025-10-02	Celgene Corporation	Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en)	2022-05-11	2023-11-16	Juno Therapeutics, Inc.	Methods and uses related to t cell therapy and production of same
WO2024069240A2 (en)	2022-09-29	2024-04-04	Takeda Pharmaceutical Company Limited	Cd38-binding fusion protein combination therapy
EP4611798A1 (de)	2022-11-02	2025-09-10	Celgene Corporation	Behandlungsverfahren mit t-zelltherapie und immunmodulatorischer mittelerhaltungstherapie
CN116768972A (zh) *	2023-06-25	2023-09-19	重庆药友制药有限责任公司	一种卡非佐米中间体的制备方法
WO2025035020A2 (en)	2023-08-09	2025-02-13	Amgen Inc.	Methods of using carfilzomib
EP4685151A1 (de)	2024-07-24	2026-01-28	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Proteasomhemmer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US569748A (en)		1896-10-20		Henry edmunds
US4733665C2 (en)	1985-11-07	2002-01-29	Expandable Grafts Partnership	Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5071957A (en)	1989-08-04	1991-12-10	Bristol-Myers Company	Antibiotic BU-4061T
US4990448A (en)	1989-08-04	1991-02-05	Bristol-Myers Company	Bu-4061T
US5340736A (en)	1991-05-13	1994-08-23	The President & Fellows Of Harvard College	ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
WO1998010779A1 (en)	1996-09-13	1998-03-19	New York University	Method for treating parasitic diseases with proteasome inhibitors
US6099851A (en) *	1998-06-02	2000-08-08	Weisman; Kenneth M.	Therapeutic uses of leuprolide acetate
US6838436B1 (en)	1998-07-10	2005-01-04	Osteoscreen Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en)	1998-07-10	2002-10-08	Osteoscreen, Inc.	Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en)	1998-07-10	2005-06-07	Osteoscreen, Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en)	1998-08-07	2001-03-20	Universtiy Of Kansas	Water soluble prodrugs of hindered alcohols
US6492333B1 (en)	1999-04-09	2002-12-10	Osteoscreen, Inc.	Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) *	1999-05-12	2004-12-14	Yale University	Enzyme inhibition
EP1716861A3 (de)	1999-10-20	2007-08-29	Osteoscreen, Inc.	Hemmstoffe der proteasom Aktivität zur Stimulierung von Knochen- und Haarwachstum
WO2003059898A2 (en)	2002-01-08	2003-07-24	Eisai Co. Ltd.	Eponemycin and epoxomicin analogs and uses thereof
US7232818B2 (en) *	2004-04-15	2007-06-19	Proteolix, Inc.	Compounds for enzyme inhibition
CN103554222A (zh) *	2004-04-15	2014-02-05	欧尼斯治疗公司	用于抑制蛋白酶体酶的化合物
AU2005243140A1 (en)	2004-05-10	2005-11-24	Proteolix, Inc.	Synthesis of amino acid keto-epoxides
ES2510840T3 (es)	2004-05-10	2014-10-21	Onyx Therapeutics, Inc.	Compuestos para la inhibición enzimática del proteosoma

2005
- 2005-04-14 US US11/106,879 patent/US7232818B2/en not_active Expired - Lifetime
- 2005-08-08 KR KR1020077003533A patent/KR101354280B1/ko not_active Expired - Lifetime
- 2005-08-08 EP EP16166492.5A patent/EP3101026B1/de not_active Expired - Lifetime
- 2005-08-08 EP EP10012497.3A patent/EP2270026B1/de not_active Expired - Lifetime
- 2005-08-08 PL PL05784484T patent/PL1781688T3/pl unknown
- 2005-08-08 US US11/199,899 patent/US7417042B2/en active Active
- 2005-08-08 PT PT161664925T patent/PT3101026T/pt unknown
- 2005-08-08 EP EP05784484A patent/EP1781688B1/de not_active Expired - Lifetime
- 2005-08-08 DE DE602005026019T patent/DE602005026019D1/de not_active Expired - Lifetime
- 2005-08-08 SI SI200532211T patent/SI3101026T1/en unknown
- 2005-08-08 CN CN201110145272.7A patent/CN102286070B/zh not_active Expired - Lifetime
- 2005-08-08 CA CA2589765A patent/CA2589765C/en not_active Expired - Lifetime
- 2005-08-08 ES ES10012498.1T patent/ES2525248T3/es not_active Expired - Lifetime
- 2005-08-08 PT PT05784484T patent/PT1781688E/pt unknown
- 2005-08-08 LT LTEP16166492.5T patent/LT3101026T/lt unknown
- 2005-08-08 JP JP2007525077A patent/JP4743720B2/ja not_active Expired - Lifetime
- 2005-08-08 AT AT05784484T patent/ATE496062T1/de active
- 2005-08-08 HU HUE16166492A patent/HUE038005T2/hu unknown
- 2005-08-08 BR BR122020008634A patent/BR122020008634B8/pt active IP Right Grant
- 2005-08-08 KR KR1020137016063A patent/KR20130080064A/ko not_active Withdrawn
- 2005-08-08 ES ES16166492.5T patent/ES2674277T3/es not_active Expired - Lifetime
- 2005-08-08 EP EP10012498.1A patent/EP2266999B1/de not_active Expired - Lifetime
- 2005-08-08 DK DK05784484.7T patent/DK1781688T3/da active
- 2005-08-08 AU AU2005271232A patent/AU2005271232B2/en active Active
- 2005-08-08 SG SG10201701794UA patent/SG10201701794UA/en unknown
- 2005-08-08 PL PL16166492T patent/PL3101026T3/pl unknown
- 2005-08-08 SI SI200531264T patent/SI1781688T1/sl unknown
- 2005-08-08 IL IL181127A patent/IL181127A/en active Protection Beyond IP Right Term
- 2005-08-08 DK DK16166492.5T patent/DK3101026T3/en active
- 2005-08-08 BR BRPI0514102A patent/BRPI0514102B8/pt active IP Right Grant
- 2005-08-08 WO PCT/US2005/028246 patent/WO2006017842A1/en not_active Ceased
- 2005-08-08 KR KR1020127030701A patent/KR101544258B1/ko not_active Expired - Lifetime
- 2005-08-08 SG SG200905204-4A patent/SG155187A1/en unknown
2007
- 2007-02-20 NO NO20070965A patent/NO341015B1/no unknown
- 2007-04-11 US US11/786,217 patent/US7491704B2/en not_active Expired - Lifetime
2011
- 2011-03-04 JP JP2011047047A patent/JP5394423B2/ja not_active Expired - Lifetime
- 2011-04-04 CY CY20111100347T patent/CY1116771T1/el unknown
2012
- 2012-08-22 IL IL221572A patent/IL221572B/en active IP Right Grant
2014
- 2014-08-06 US US14/452,844 patent/US20140342977A1/en not_active Abandoned
2015
- 2015-08-26 US US14/835,876 patent/US20150361134A1/en not_active Abandoned
2016
- 2016-04-05 HU HUS1600014C patent/HUS1600014I1/hu unknown
- 2016-04-06 LU LU93015C patent/LU93015I2/xx unknown
- 2016-04-08 US US15/094,088 patent/US20160222057A1/en not_active Abandoned
- 2016-04-12 LT LTPA2016010C patent/LTC1781688I2/lt unknown
- 2016-04-22 CY CY2016009C patent/CY2016009I2/el unknown
- 2016-05-12 FR FR16C0017C patent/FR16C0017I2/fr active Active
2017
- 2017-03-14 NO NO20170381A patent/NO344397B1/no unknown
2018
- 2018-02-13 US US15/895,120 patent/US20180170962A1/en not_active Abandoned
- 2018-06-20 CY CY181100642T patent/CY1120677T1/el unknown
- 2018-09-20 IL IL261892A patent/IL261892B/en active IP Right Grant
2019
- 2019-03-13 US US16/351,669 patent/US20190211058A1/en not_active Abandoned
- 2019-10-31 US US16/669,601 patent/US20200071356A1/en not_active Abandoned
2020
- 2020-06-26 US US16/912,806 patent/US20200325172A1/en not_active Abandoned
2021
- 2021-02-08 US US17/169,990 patent/US20210179663A1/en not_active Abandoned
2022
- 2022-04-29 US US17/733,077 patent/US20220267372A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR101544258B1 (ko)	2015-08-21
BR122020008634B1 (pt)	2021-02-17
DK3101026T3 (en)	2018-06-18
CY2016009I1 (el)	2016-08-31
EP2266999B1 (de)	2014-09-24
IL181127A (en)	2013-03-24
SG10201701794UA (en)	2017-04-27
SG155187A1 (en)	2009-09-30
EP2266999A2 (de)	2010-12-29
CY1120677T1 (el)	2019-12-11
CA2589765C (en)	2015-06-30
NO20070965L (no)	2007-04-16
WO2006017842A1 (en)	2006-02-16
FR16C0017I2 (fr)	2016-08-26
PL3101026T3 (pl)	2018-12-31
EP2266999A3 (de)	2011-09-14
BR122020008634B8 (pt)	2021-07-27
US20180170962A1 (en)	2018-06-21
US20140342977A1 (en)	2014-11-20
SI3101026T1 (en)	2018-08-31
PT1781688E (pt)	2011-04-05
US20050245435A1 (en)	2005-11-03
US7232818B2 (en)	2007-06-19
BRPI0514102B1 (pt)	2020-07-07
HK1152536A1 (en)	2012-03-02
KR101354280B1 (ko)	2014-01-23
HK1103525A1 (en)	2007-12-21
LU93015I2 (fr)	2016-06-06
AU2005271232A1 (en)	2006-02-16
DK1781688T3 (da)	2011-03-14
EP2270026A2 (de)	2011-01-05
CY2016009I2 (el)	2016-08-31
HUS1600014I1 (hu)	2016-05-30
NO344397B1 (no)	2019-11-25
ES2525248T3 (es)	2014-12-19
LTPA2016010I1 (lt)	2016-04-25
US20200071356A1 (en)	2020-03-05
EP1781688B1 (de)	2011-01-19
IL261892A (en)	2018-10-31
KR20130080064A (ko)	2013-07-11
IL221572A0 (en)	2012-10-31
HK1231491A1 (en)	2017-12-22
BRPI0514102A (pt)	2008-05-27
HUE038005T2 (hu)	2018-09-28
AU2005271232B2 (en)	2012-07-05
SI1781688T1 (sl)	2011-05-31
EP2270026B1 (de)	2016-05-18
US7417042B2 (en)	2008-08-26
DE602005026019D1 (de)	2011-03-03
CN102286070A (zh)	2011-12-21
US20150361134A1 (en)	2015-12-17
US7491704B2 (en)	2009-02-17
IL221572B (en)	2018-10-31
US20060030533A1 (en)	2006-02-09
US20220267372A1 (en)	2022-08-25
IL181127A0 (en)	2007-07-04
LT3101026T (lt)	2018-07-10
KR20070047780A (ko)	2007-05-07
US20200325172A1 (en)	2020-10-15
US20210179663A1 (en)	2021-06-17
EP1781688A1 (de)	2007-05-09
US20190211058A1 (en)	2019-07-11
IL261892B (en)	2019-12-31
US20070191284A1 (en)	2007-08-16
ES2674277T3 (es)	2018-06-28
US20160222057A1 (en)	2016-08-04
PL1781688T3 (pl)	2011-06-30
KR20120135355A (ko)	2012-12-12
BRPI0514102B8 (pt)	2021-05-25
NO341015B1 (no)	2017-08-07
CY1116771T1 (el)	2016-08-31
EP3101026A1 (de)	2016-12-07
NO20170381A1 (no)	2007-04-16
HK1152716A1 (en)	2012-03-09
JP4743720B2 (ja)	2011-08-10
JP2008509166A (ja)	2008-03-27
FR16C0017I1 (de)	2016-06-24
CA2589765A1 (en)	2006-02-16
CN102286070B (zh)	2014-12-10
EP2270026A3 (de)	2011-09-14
JP2011148805A (ja)	2011-08-04
LTC1781688I2 (lt)	2017-09-25
PT3101026T (pt)	2018-08-03
JP5394423B2 (ja)	2014-01-22
EP3101026B1 (de)	2018-03-28

Legal Events

Date

Code

Title

Description

2011-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1781688

Country of ref document: EP

Publication	Publication Date	Title
ATE496062T1 (de)	2011-02-15	Verbindungen zur proteasomenzymhemmung
ATE494298T1 (de)	2011-01-15	Verbindungen zur proteasomenzymhemmung
EP2564834A3 (de)	2013-08-21	Verbindungen zur Proteasomenzyminhibition
MY145757A (en)	2012-04-13	Compounds for enzyme inhibition
WO2008140782A3 (en)	2008-12-31	Compounds for enzyme inhibition
WO2006045066A3 (en)	2006-08-31	Labeled compounds for proteasome inhibition
CR9962A (es)	2008-10-17	Compuestos para inhibicion enzimatica